Angitia Biopharmaceuticals Reveals AGA2115 Data for Osteogenesis Imperfecta

Posted: September 8, 2025
Angitia Biopharmaceuticals reveals promising first-in-human data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025. The presentation highlighted dose-dependent increases in bone mineral density. Collaborative efforts with the Company also showcased significant advancements in the field.

This article summary was generated by AI. To view the full article, click the link here: https://www.globenewswire.com/news-release/2025/09/08/3146019/0/en/Angitia-Biopharmaceuticals-Presents-First-in-Human-Data-on-AGA2115-for-Osteogenesis-Imperfecta-at-ASBMR-2025.html
Views: 1
Sponsors
Townie Perks
Townie® Poll
This is the poll questions
  
The Dentaltown Team, Member Services Specialist
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2026 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450